Synaptogenix Regains Compliance With Nasdaq Minimum Bid Price Requirement for Continued Listing
Synaptogenix Regains Compliance With Nasdaq Minimum Bid Price Requirement for Continued Listing
NEW YORK, April 24, 2024 /PRNewswire/ -- Synaptogenix, Inc. (Nasdaq: SNPX) ("Synaptogenix" or the "Company"), an emerging biopharmaceutical company developing therapeutics for neurodegenerative disorders, today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on April 22, 2024, informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) ("Listing Rule") for continued listing on The Nasdaq Capital Market.
紐約，2024年4月24日 /PRNewswire/ — 開發神經退行性疾病療法的新興生物製藥公司Synaptogenix, Inc.（納斯達克股票代碼：SNPX）（“Synaptogenix” 或 “公司”）今天宣佈，它已於2024年4月22日收到納斯達克股票市場有限責任公司（“納斯達克”）的通知，通知該公司已恢復遵守該協議納斯達克上市規則5550 (a) (2)（“上市規則”）下的最低出價要求才能繼續在納斯達克資本市場上市。
On April 24, 2023, Synaptogenix received notice from the Listing Qualifications Department of Nasdaq indicating that the Company was not in compliance with the Listing Rule, as its common stock had failed to meet a closing bid price of $1.00 or more for 30 consecutive business days. In order to regain compliance with the Listing Rule, the Company's common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days. The Company conducted a 1-for-25 reverse split of its common stock on April 4, 2024, with the goal of increasing the trading price of the common stock. The common stock began trading on a split-adjusted basis on April 5, 2024, under the new CUSIP number 87167T 300.
2023年4月24日，Synaptogenix收到納斯達克上市資格部門的通知，表明該公司未遵守上市規則，因爲其普通股連續30個工作日未能達到1.00美元或以上的收盤價。爲了重新遵守上市規則，公司普通股必須至少連續10個工作日將最低收盤價維持在1.00美元或以上。該公司於2024年4月4日對其普通股進行了1比25的反向拆分，目標是提高普通股的交易價格。普通股於2024年4月5日開始按拆分調整後的基礎上交易，新的CUSIP編號爲87167T 300。
About Synaptogenix
關於 Synaptogenix
Synaptogenix is a clinical-stage biopharmaceutical company that has historically worked to develop novel therapies for neurodegenerative diseases. Synaptogenix has conducted clinical and preclinical studies of its lead therapeutic candidate, Bryostatin-1, in Alzheimer's disease. Preclinical studies have also demonstrated bryostatin's regenerative mechanisms of action for the rare disease Fragile X syndrome, and for other neurodegenerative disorders such as multiple sclerosis, stroke, and traumatic brain injury. The U.S. Food and Drug Administration has granted Orphan Drug Designation to Synaptogenix for Bryostatin-1 as a treatment for Fragile X syndrome. Bryostatin-1 has already undergone testing in more than 1,500 people in cancer studies, thus creating a large safety data base that will further inform clinical trial designs. Additional information about Synaptogenix, Inc. may be found on its website:
Synaptogenix是一家臨床階段的生物製藥公司，歷來致力於開發神經退行性疾病的新療法。Synaptogenix已對其主要的阿爾茨海默氏病候選治療藥物Bryostatin-1進行了臨床和臨床前研究。臨床前研究還表明，bryostatin對罕見的脆性X綜合徵和其他神經退行性疾病（例如多發性硬化、中風和創傷性腦損傷）具有再生作用機制。美國食品藥品監督管理局已授予Synaptogenix孤兒藥稱號，用於治療脆性X綜合徵的Bryostatin-1。Bryostatin-1已經在癌症研究中對1,500多人進行了測試，從而創建了一個龐大的安全數據庫，將進一步爲臨床試驗設計提供信息。有關 Synaptogenix, Inc. 的其他信息可以在其網站上找到：
Contact
聯繫我們
800-811-5591
[email protected]
800-811-5591
[電子郵件保護]
SOURCE Synaptogenix, Inc.
來源 Synaptogenix, Inc.
譯文內容由第三人軟體翻譯。